In particular, alum adjuvant in FI-RSV vaccine formulations has considerable impacts on increasing immunogenicity and virus clearance as well as Th2 type CD4 T cells, proinflammatory cytokines, eosinophilia, mucus production, B220+ pDCs, and CD4+ DCs, and inhibition of effector CD8 T cells. The gene discussed is PTPRC; the disease is Increased total eosinophil count.